JeremyW.RuponMD

PubMed

• 1 citations
  Giroctocogene fitelparvovec gene therapy for severe hemophilia A: 104-week analysis of the phase 1/2 Alta study.
  Andrew D Leavitt, Barbara A Konkle, Kimo C Stine, Nathan Visweshwar, Thomas J Harrington, Adam Giermasz, Steven Arkin, Annie Fang, Frank Plonski, Anne Yver, Florence G...> ;Blood. 2024 Feb 29
• Nonacog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Moderately Severe or Severe Hemophilia B in India.
  Nirmalkumar Choraria, Savita Rangarajan, M Joseph John, Shashikant Apte, Pritam Gupta, Seema Pai, Rohit Chand, Shyam Parvatini, G S H Ramakanth, Jeremy Rupon, Amit Chh...> ;Indian Journal of Hematology & Blood Transfusion. 2023 Oct 1
• 1 citations
  Forced enhancer-promoter rewiring to alter gene expression in animal models.
  Scott A Peslak, Selami Demirci, Vemika Chandra, Byoung Ryu, Saurabh K Bhardwaj, Jing Jiang, Jeremy W Rupon, Robert E Throm, Naoya Uchida, Alexis Leonard, Khaled Essawi...> ;Molecular Therapy. Nucleic Acids. 2023 Mar 14
• Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Patients with Hemophilia A in India.
  Nirmalkumar Choraria, Savita Rangarajan, M Joseph John, Shashikant Apte, Pritam Gupta, Seema Pai, Rohit Chand, Shyam Parvatini, G S H Ramakanth, Jeremy Rupon, Amit Chh...> ;Indian Journal of Hematology & Blood Transfusion. 2022 Nov 27
• First open-label, single-arm, prospective study of real-world use of FIX replacement therapy in a predominantly pediatric hemophilia B population in China.
  Renchi Yang, Runhui Wu, Jing Sun, Feifei Sun, Jeremy Rupon, Francois Huard, Joan M. Korth-Bradley, Lihong Xu, Binyu Luo, Yingxue Cathy Liu, Pablo Rendo> ;Medicine. 2021 May 28
• 16 citations
  Factor IX Assay Discrepancies in the Setting of Liver Gene Therapy Using a Hyperfunctional Variant Factor IX‐Padua
  Mary Robinson, Lindsey A. George, Marcus E. Carr, Benjamin J. Samelson-Jones, Valder R. Arruda, John E. Murphy, Denis Rybin, Jeremy Rupon, Katherine A. High, Stefan Ti...> ;Journal of Thrombosis and Haemostasis. 2021 Feb 26
• 1 citations
  Safety and Efficacy of Moroctocog Alfa (AF-CC) in Chinese Patients with Hemophilia A: Results of Two Open-Label Studies
  Renchi Yang, Yongqiang Zhao, Xuefeng Wang, Jing Sun, Runhui Wu, Chenghao Jin, Jie Jin, Depei Wu, Pablo Rendo, Feifei Sun, Jeremy Rupon, Francois Huard, Joan M. Korth-B...> ;Journal of Blood Medicine. 2020 Nov 25
• Impact of treatment regimen with moroctocog alfa (AF-CC) on bleeding rates in paediatric patients with severe haemophilia A.
  Mark Smith, Jeremy Rupon, Yasser Wali, Hala Rimawi, Joan M. Korth-Bradley, Lynne Smith, Pablo Rendo> ;Haemophilia. 2020 Jun 4
• 11 citations
  Outcomes of a clinical pathway for primary outpatient management of pediatric patients with low-risk febrile neutropenia.
  Jonathan Paolino, Juliana Mariani, Alexandra Lucas, Jeremy Rupon, Howard J. Weinstein, Annah N. Abrams, Alison M. Friedmann> ;Pediatric Blood & Cancer. 2019 Jul 1
• 5 citations
  Clinical experience with moroctocog alfa (AF-CC) in younger paediatric patients with severe haemophilia A: Two open-label studies.
  L. Rusen, Kaan Kavakli, Joan M. Korth-Bradley, Francois Huard, Pablo Rendo, Joanne Fuiman, James Baumann, Lynne Smith, Christine Alvey, Jeremy Rupon> ;Haemophilia. 2018 Jul 1
• 3 citations
  Assessment of Relative Bioavailability of Moroctocog Alfa and Moroctocog Alfa (AF-CC) in Subjects With Severe Hemophilia A.
  Joan M. Korth-Bradley, Jeremy Rupon, Anna Plotka, Robert J Charnigo, Pablo Rendo> ;Clinical and Translational Science. 2018 May 1
• 59 citations
  Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers
  Laura Breda, Irene Motta, Lourenco Silvia Pires, Chiara Gemmo, Wulan Deng, Jeremy Rupon, Osheiza Abdulmalik, Deepa Manwani, Gerd A. Blobel, Stefano Rivella> ;Blood. 2016 Aug 25
• 297 citations
  Reactivation of developmentally silenced globin genes by forced chromatin looping.
  Wulan Deng, Jeremy Rupon, Ivan Krivega, Laura Breda, Irene Motta, Kristen S. Jahn, Andreas Reik, Philip D. Gregory, Stefano Rivella, Ann Dean, Gerd A. Blobel> ;Cell. 2014 Aug 14
• 1 citations
  Presentation of hemophagocytic lymphohistiocytosis due to a novel MUNC 13–4 mutation masked by partial therapeutic immunosuppression
  Jackie P.-D. Garrett, Irene Fung, Jeremy Rupon, Andrea M. Knight, Melissa C. Mizesko, Michelle Paessler, Jordan S. Orange> ;Pediatric Rheumatology Online Journal. 2012 May 3
• 13 citations
  MBD2 contributes to developmental silencing of the human ε-globin gene
  Jeremy W. Rupon, Shou Zhen Wang, Merlin Nithya Gnanapragasam, Stefanos Labropoulos, Gordon D. Ginder> ;Blood Cells, Molecules & Diseases. 2011 Mar 15
• 35 citations
  MBD2 is a critical component of a methyl cytosine-binding protein complex isolated from primary erythroid cells
  Evan P. Kransdorf, Shou Zhen Wang, Sheng Zu Zhu, Timothy B. Langston, Jeremy W. Rupon, Gordon D. Ginder> ;Blood. 2006 Oct 15
• 53 citations
  Methyl binding domain protein 2 mediates γ-globin gene silencing in adult human βYAC transgenic mice
  Jeremy W. Rupon, Shou Zhen Wang, Karin M.L. Gaensler, Joyce A. Lloyd, Gordon D. Ginder> ;Proceedings of the National Academy of Sciences of the United States of America. 2006 Apr 25
• 52 citations
  A functional screen for Krüppel-like factors that regulate the human γ-globin gene through the CACCC promoter element
  Ping Zhang, Priyadarshi Basu, Latasha C. Redmond, Pamela E. Morris, Jeremy W. Rupon, Gordon D. Ginder, Joyce A. Lloyd> ;Blood Cells, Molecules & Diseases. 2005 Sep 1
• 30 citations
  Iron nitrosyl hemoglobin formation from the reactions of hemoglobin and hydroxyurea.
  Jinming Huang, Shreeshailkumar B Hadimani, Jeremy W. Rupon, Samir K. Ballas, Daniel B. Kim-Shapiro, S. Bruce King> ;Biochemistry. 2002 Jan 23
• 21 citations
  The reactions of myoglobin, normal adult hemoglobin, sickle cell hemoglobin and hemin with hydroxyurea
  Jeremy W. Rupon, Shirely R. Domingo, Sara V. Smith, Bharat K. Gummadi, Howard Shields, Samir K. Ballas, S. Bruce King, Daniel B. Kim-Shapiro> ;Biophysical Chemistry. 2000 Feb 14
• Join now to see all

Abstracts/Posters

• Efficacy and Safety in 15 Hemophilia B Patients Treated with the AAV Gene Therapy Vector Fidanacogene Elaparvovec and Followed for at Least 1 Year
  Jeremy Rupon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019